BRCA1 is altered in 5.82% of transitional cell carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and transitional cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

BRCA2 is altered in 8.2% of transitional cell carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

FGFR1 is altered in 3.47% of transitional cell carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 3 clinical trials for transitional cell carcinoma, of which 0 are open and 3 are closed. Of the trials that contain FGFR1 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), and 1 is phase 2/phase 3 (0 open) [3].

FGFR2 is altered in 2.84% of transitional cell carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for transitional cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR3 is altered in 27.83% of transitional cell carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 3 clinical trials for transitional cell carcinoma, of which 0 are open and 3 are closed. Of the trials that contain FGFR3 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), and 1 is phase 2/phase 3 (0 open) [3].

FGFR4 is altered in 2.0% of transitional cell carcinoma patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for transitional cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR4 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TSC1 is altered in 9.8% of transitional cell carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 3.99% of transitional cell carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].